PET/CT in Gynecological Cancers

Foreword\nPreface\nAcknowledgements\nContents\nContributors\n1: Gynaecological Malignancies: Epidemiology, Clinical Presentation, Diagnosis, Staging and Staging Procedures\n	1.1	 Cervical Cancer\n		1.1.1	 Epidemiology\n		1.1.2	 Classification\n		1.1.3	 Aetiology\n		1.1.4	 Clinical Presentation\n		1.1.5	 Diagnosis\n		1.1.6	 Staging\n	1.2	 Endometrial Cancer\n		1.2.1	 Epidemiology\n		1.2.2	 Classification\n		1.2.3	 Aetiology\n		1.2.4	 Clinical Presentation\n		1.2.5	 Diagnosis\n		1.2.6	 Staging\n	1.3	 Ovarian Cancer\n		1.3.1	 Epidemiology\n		1.3.2	 Classification\n		1.3.3	 Aetiology\n		1.3.4	 Clinical Presentation\n		1.3.5	 Diagnosis\n		1.3.6	 Staging\n	References\n2: An Overview of the Pathology of Gynaecological Cancers\n	2.1	 Cervix\n	2.2	 Endometrium\n	2.3	 Ovary\n	Further Reading\n3: An Overview of the Management of Gynaecological Cancers\n	3.1	 Cervical Cancer\n		3.1.1	 Management of Primary Cervical Cancer\n		3.1.2	 Management of Recurrent Cervical Cancer\n	3.2	 Uterine Cancer\n		3.2.1	 Management of Primary Uterine Cancer\n		3.2.2	 Management of Recurrent Disease\n	3.3	 Ovarian Cancer\n	References\n4: Radiological Imaging in Gynaecological Malignancies\n	4.1	 Normal Anatomy\n	4.2	 Imaging Modalities and Technique\n	4.3	 Cervical Cancer\n		4.3.1	 Primary Diagnosis/Staging\n		4.3.2	 Follow-Up\n		4.3.3	 Limitations/Pitfalls of MRI\n	4.4	 Endometrial Cancer\n		4.4.1	 Primary Diagnosis/Staging\n			4.4.1.1	 Ultrasound\n			4.4.1.2	 MRI\n		4.4.2	 Limitations/Pitfalls\n			4.4.2.1	 CECT\n		4.4.3	 Recurrent Disease\n	4.5	 Ovarian Cancer\n		4.5.1	 Primary Diagnosis/Staging\n		4.5.2	 Limitations/Pitfalls\n		4.5.3	 Response Assessment\n	4.6	 Nodal Evaluation\n	References\n5: Basic Principles of PET-CT Imaging\n	5.1	 Introduction\n	5.2	 Positron Emission Tomography (PET)\n	5.3	 PET Scanning\n	5.4	 Imaging with [fluorine-18] FDG PET\n	5.5	 Artefacts\n	References\n6: 18F-FDG and Non-FDG PET Radiopharmaceuticals\n	6.1	 Introduction\n	6.2	 PET Radiopharmaceuticals\n		6.2.1	 18F-FDG\n	6.3	 Non-FDG Radiopharmaceuticals\n	Conclusion\n	References\n7: PET/CT Imaging: Patient Instructions and Preparation\n	7.1	 Introduction\n	7.2	 Patient Preparation\n	7.3	 Timing of FDG PET Scan After Treatment\n	References\n8: 18F-FDG PET/CT Imaging: Normal Variants, Pitfalls and Artefacts\n	8.1	 Introduction\n	Conclusions\n	References\n9: PET/CT in Gynaecological Malignancies\n	9.1	 Introduction\n	9.2	 Technical Aspects and Limitations of PET/CT Specific to Gynaecological Malignancies\n	9.3	 Cervical Cancer\n		9.3.1	 Staging Primary Cervical Cancer\n		9.3.2	 Recurrence\n	9.4	 Endometrial Cancer\n		9.4.1	 Primary Staging of Endometrial Cancer\n		9.4.2	 Recurrence\n	9.5	 Ovarian Cancer\n		9.5.1	 Characterisation of Adnexal Masses\n		9.5.2	 Primary Staging\n		9.5.3	 Ovarian Cancer Relapse\n	9.6	 Future Roles\n		9.6.1	 Radiotherapy Planning\n		9.6.2	 Prognostic Information\n		9.6.3	 Early Response Assessment\n		9.6.4	 Technical Advances\n		9.6.5	 New Tracers\n	9.7	 Summary\n	References\n10: PET/CT in Gynaecological Malignancies: Pictorial Atlas\nIndex